IntensVIH: Impact Of Therapy Intensification By An Integrase Inhibitor +/- CCR5 Inhibitor On The Lymphoid Reservoir For Hiv-1 In Chronically Infected Patients

Inclusion Criteria: * Male or female patients, aged over 18 years * HIV infection confirmed by Western Blot * Karnofsky score \> 80% * Treatment-experienced patients having received combined antiretroviral therapy including at least 2 RTI and 1 PI/r for at least 12 months with plasma viral load \<50 copies/ml for at least 6 months * Stable first-line treatment (or other, if changes were not made for reasons relating to viral resistance) with 2 RTIs and 1 PI/r * Proper safety and compliance for the ongoing combination; * Patient agreeing to undergo 3 proctosigmoidoscopy examinations over a 12-month period; * Plasma HIV-1 RNA \<50 copies/ml at inclusion; * Circulating CD4 \>200/mm3 at inclusion; * Isentress® and Celsentri®-naïve patients * No contraindications to the use of the investigational products * Written, informed consent, obtained from the patient or his/her legal representative. Exclusion Criteria: 1. Opportunistic infection or active tumor disease 2. Chronic diarrhea, malabsorption, progressive enteric infection 3. Aged under 18 years 4. Pregnancy - breast-feeding ( a pregnancy test will be done at the inclusion visit) 5. Co-infection with HIV-2 6. History of immunomodulator treatment (interleukin-2, alpha-interferon) 7. Ongoing treatment of HBV or HCV co-infection 8. Blood constitution disorders 9. Contraindications to the administration of raltegravir or maraviroc 10. Circulating CD4 nadir \<100/mm3 in the natural history of HIV-1 infection.